Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02191982
Other study ID # LCCC1402
Secondary ID
Status Completed
Phase N/A
First received June 20, 2014
Last updated September 11, 2017
Start date June 2014
Est. completion date August 2017

Study information

Verified date September 2017
Source UNC Lineberger Comprehensive Cancer Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will look at the impact of a self-directed walking program on post-chemotherapy survivors experiencing fatigue. It is hypothesized that the walking program will help lessen fatigue.


Description:

The investiagors propose to evaluate the impact of a home-based self-directed walking program on post-chemotherapy fatigue among 150 cancer survivors age 65 and older -- Senior Physical Activity after Chemotherapy (S-PACT). Participants must have potentially curable cancer, moderate to severe fatigue (score of 4 or higher on the Brief Fatigue Inventory), currently exercise less than 120 minutes per week and have completed chemotherapy treatment (radiation treatment must also be completed if it is part of the patient's treatment plan) within the last 6 weeks. The design is a randomized controlled trial, with participants randomized to a 3-month physical activity program (intervention group) or to wait-list control (this group begins the walking program at 3 months post-randomization). The primary objective is to compare the change in fatigue scores from baseline to 3 months between the intervention and wait-list control groups.


Recruitment information / eligibility

Status Completed
Enrollment 44
Est. completion date August 2017
Est. primary completion date August 2017
Accepts healthy volunteers No
Gender All
Age group 65 Years and older
Eligibility Inclusion Criteria:

- Men and women age 65 years and older

- Histologically or cytologically confirmed cancer (hematologic or solid) at stage considered amenable to cure as assessed by the treating MD

- Within 6 weeks of end of chemotherapy (all participants must have had chemotherapy treatment)

- Any radiation received must also be completed prior to randomization (if radiation treatment follows adjuvant chemotherapy, then the patient must be recruited within 6 weeks of end of radiation)

- Maintenance hormonal therapy in women with breast cancer is allowed; see exclusion criteria regarding hormonal therapy in males with prostate cancer

- Moderate to severe fatigue (>4 on BFI)

- Less than 120 minutes/week of physical activity

- English speaking

- Signed IRB approved written informed consent

- Approval from their treating physician to engage in moderate-intensity physical activity

- Patient-assessed ability to walk and engage in moderate physical activity

- Willing and able to meet all study requirements.

Exclusion Criteria:

- Receiving hormonal therapy for prostate cancer

- Unable to walk or engage in moderate-intensity physical activity

- Have BFI=3.

- Report more than 120 minutes/week of physical activity

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Walk With Ease
Walk With Ease is the Arthritis Foundation's evidence-based walking intervention to help with fatigue and pain. The intervention is a self-directed program that helps guide participants in a safe and comfortable paced walking program with an ultimate goal of walking for 30 minutes a day, five days a week.

Locations

Country Name City State
United States University of North Carolina Chapel Hill North Carolina

Sponsors (2)

Lead Sponsor Collaborator
UNC Lineberger Comprehensive Cancer Center Breast Cancer Research Foundation

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary To measure change in fatigue scores between intervention and wait list control arms from baseline to three months. Change in fatigue will be measured using the FACIT-F. Three months
Secondary To measure change in fatigue scores between intervention and WLC arms from baseline to 3 months This outcome will be measured by the Brief Fatigue Inventory Three months
Secondary To report recruitment and retention in the study at 3 months Three months
Secondary To report recruitment and retention in the study at 6 months Six months
Secondary To measure implementation of and adherence to WWE Six months
Secondary To count the number of adverse events To characterize the safety of the walking program through a review of the number and type of adverse events, including falls, reported by study participants to the Study Team. Six months
Secondary To measure change in engagement of walking over time from baseline to three months. To evaluate the following measures at baseline and 3 months, and compare changes in these measures over time between intervention and WLC arms.
Engagement in walking (total minutes per week) as measured by engagement in physical activity questions
Three Months
Secondary To measure change in physical function over time from baseline to three months. To evaluate the following measures at baseline and 3 months, and compare changes in these measures over time between intervention and WLC arms.
Physical function as measured by SPPB
Three Months
Secondary To measure change in quality of life over time from baseline to three months. To evaluate the following measures at baseline and 3 months, and compare changes in these measures over time between intervention and WLC arms.
Quality of life as measured by FACT-G (global and subscales) and symptom scales, including PROMIS pain intensity, sleep disturbance and depression.
Three Months
Secondary To measure change in self-efficacy over time from baseline to three months. To evaluate the following measures at baseline and 3 months, and compare changes in these measures over time between intervention and WLC arms.
Engagement in walking (total minutes per week) as measured by engagement in physical activity questions
Three Months
See also
  Status Clinical Trial Phase
Recruiting NCT05346796 - Survivorship Plan HEalth REcord (SPHERE) Implementation Trial N/A
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Completed NCT04867850 - Effect of Behavioral Nudges on Serious Illness Conversation Documentation N/A
Enrolling by invitation NCT04086251 - Remote Electronic Patient Monitoring in Oncology Patients N/A
Completed NCT01285037 - A Study of LY2801653 in Advanced Cancer Phase 1
Completed NCT00680992 - Study of Denosumab in Subjects With Giant Cell Tumor of Bone Phase 2
Completed NCT00062842 - Study of Irinotecan on a Weekly Schedule in Children Phase 1
Active, not recruiting NCT04548063 - Consent Forms in Cancer Research: Examining the Effect of Length on Readability N/A
Completed NCT04337203 - Shared Healthcare Actions and Reflections Electronic Systems in Survivorship N/A
Recruiting NCT04349293 - Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways N/A
Terminated NCT02866851 - Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy N/A
Active, not recruiting NCT05304988 - Development and Validation of the EFT for Adolescents With Cancer
Completed NCT00340522 - Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Completed NCT03109041 - Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source Phase 1
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Terminated NCT01441115 - ECI301 and Radiation for Advanced or Metastatic Cancer Phase 1
Recruiting NCT06206785 - Resting Energy Expenditure in Palliative Cancer Patients
Recruiting NCT05318196 - Molecular Prediction of Development, Progression or Complications of Kidney, Immune or Transplantation-related Diseases

External Links